JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Prothena Corp PLC

Suletud

SektorTervishoid

9.84 0.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.83

Max

9.9

Põhinäitajad

By Trading Economics

Sissetulek

-66M

-126M

Müük

1.6M

4.4M

Kasumimarginaal

-2,845.407

Töötajad

163

EBITDA

14M

-52M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+32.38% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. nov 2025

Turustatistika

By TradingEconomics

Turukapital

185M

558M

Eelmine avamishind

9.33

Eelmine sulgemishind

9.84

Uudiste sentiment

By Acuity

23%

77%

46 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Prothena Corp PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. okt 2025, 18:41 UTC

Tulu

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24. okt 2025, 18:31 UTC

Tulu

Correction to Procter & Gamble to Focus on Innovation

24. okt 2025, 16:25 UTC

Suurimad hinnamuutused turgudel

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24. okt 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. okt 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24. okt 2025, 21:07 UTC

Tulu

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24. okt 2025, 20:58 UTC

Tulu

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24. okt 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. okt 2025, 20:40 UTC

Tulu

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24. okt 2025, 20:24 UTC

Tulu

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. okt 2025, 20:23 UTC

Tulu

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. okt 2025, 20:13 UTC

Tulu

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24. okt 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24. okt 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24. okt 2025, 19:33 UTC

Tulu

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24. okt 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24. okt 2025, 18:52 UTC

Tulu

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. okt 2025, 18:41 UTC

Tulu

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. okt 2025, 18:03 UTC

Tulu

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24. okt 2025, 18:02 UTC

Tulu

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24. okt 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24. okt 2025, 16:57 UTC

Tulu

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24. okt 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24. okt 2025, 16:44 UTC

Market Talk
Tulu

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24. okt 2025, 16:39 UTC

Market Talk
Tulu

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24. okt 2025, 16:33 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 16:23 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. okt 2025, 16:07 UTC

Tulu

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Prothena Corp PLC Prognoos

Hinnasiht

By TipRanks

32.38% tõus

12 kuu keskmine prognoos

Keskmine 13 USD  32.38%

Kõrge 20 USD

Madal 4 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Prothena Corp PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

4

Osta

1

Hoia

1

Müü

Tehniline skoor

By Trading Central

N/A / 7.35Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

46 / 371 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
help-icon Live chat